Heme (Ferriprotoporphyrin IX) (FP-IX)

Heme, specifically in the form of ferriprotoporphyrin IX, is a critical metabolic byproduct and therapeutic target in malaria parasites such as Plasmodium falciparum (Sullivan et al., 1996, PNAS). During the intraerythrocytic stage of infection, the parasite digests host hemoglobin to obtain amino acids, releasing large quantities of free heme which is highly toxic due to its ability to generate reactive oxygen species (Egan, 2008, J. Chem. Biol.). To survive, the parasite detoxifies this heme by biocrystallizing it into an insoluble polymer called hemozoin (Hempelmann, 2007, Parasitol. Res.). Antimalarial drugs like chloroquine and quinine target this process by binding to heme and preventing its incorporation into hemozoin, leading to toxic heme accumulation and parasite death (Combrinck et al., 2013, ACS Chem. Biol.). Furthermore, heme serves as the primary activator for artemisinin-based drugs, where the iron in heme triggers the formation of parasiticidal free radicals (Tilley et al., 2016, Nat. Rev. Microbiol.). This unique metabolic vulnerability makes heme detoxification one of the most successful targets in the history of antimalarial chemotherapy (PubChem CID 5460372).

Other names

Ferriprotoporphyrin IXHematinProtohemeFP-IXMalaria pigment precursor

Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free heme which causes oxidative damage and parasite death; also acts as a chemical activator for artemisinin-based drugs.